Combinatorially selected guanosine-quartet structureis a potent inhibitor of human immunodeficiency virus envelope-mediated cellfusion.
Jacqueline R. Wyatt(Ionis Pharmaceuticals (United States)), Timothy A. Vickers(Ionis Pharmaceuticals (United States)), Joseph L. Roberson(Ionis Pharmaceuticals (United States)), Robert W. Buckheit(Ionis Pharmaceuticals (United States)), Thomas Klimkait(Ionis Pharmaceuticals (United States)), Elizabeth L. DeBaets(Ionis Pharmaceuticals (United States)), Peter W. Davis(Ionis Pharmaceuticals (United States)), Bernard Rayner(Ionis Pharmaceuticals (United States)), J.‐L. IMBACH(Ionis Pharmaceuticals (United States)), David J. Ecker(Ionis Pharmaceuticals (United States))
Cited by 300Open Access
Abstract
The phosphorothioate oligonucleotide T2G4T2 was identified as an inhibitor of HIV infection in vitro by combinatorial screening of a library of phosphorothioate oligonucleotides that contained all possible octanucleotide sequences. The oligonucleotide forms a parallel-stranded tetrameric guanosine-quartet structure. Tetramer formation and the phosphorothioate backbone are essential for antiviral activity. The tetramer binds to the human immunodeficiency virus envelope protein gp120 at the V3 loop and inhibits both cell-to-cell and virus-to-cell infection.
Related Papers
No related papers found
Powered by citation graph analysis